

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. EDE, Ronald Hao Xi has been appointed as a non-executive director of the Company, such appointment to take effect from 15 June 2015.

The board of directors (the “Board”) of Dawnrays Pharmaceutical (Holdings) Limited (the “Company”) is pleased to announce that Mr. EDE, Ronald Hao Xi (“Mr. Ede”) has been appointed as a non-executive director of the Company, such appointment to take effect from 15 June 2015.

Mr. EDE, Ronald Hao Xi, aged 56, has extensive experience in financial and business management in multinational companies. He currently holds the position of chief financial officer and company secretary of Biosensors International Group Ltd., a listed company on the Singapore Exchange. He is also an independent director and a member of the audit committee and transactions committee of Mindray Medical International Ltd., a company listed on The New York Stock Exchange. Mr. Ede obtained his Bachelor degree in Business Administration from The University of Hawaii and a Master of Business Administration degree from The University of Washington.

As at the date of this announcement, Mr. Ede does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and he does not have any relationships with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Ede (i) does not hold any positions in the Company or its subsidiaries; (ii) did not hold in the last three years other directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas.

Mr. Ede has entered into a letter of appointment with the Company for a term of two years which will commence on 15 June 2015 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association

of the Company. His appointment may be terminated by either party on not less than one month's written notice. Under the terms of his letter of appointment, Mr. Ede will be entitled to an annual remuneration of HK\$180,000 or such other sum that the Board may from time to time decide which is determined based on prevailing market practice, his duties, responsibilities, contribution to the Company and the remuneration of other non-executive directors of the Company.

There is no information, other than those set out above, that needs to be disclosed pursuant to any of the requirements as set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter that needs to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. Ede.

The Board would like to express its warmest welcome to Mr. Ede for joining the Company.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 12 June 2015

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Li Tung Ming; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Pan Xue Tian, Mr. Choi Tat Ying Jacky and Mr. Lo Tung Sing Tony.

**For identification purpose only*